4Siegel R,Ma J,Zou Z,et al. Cancer statistics,2014 [J]. CA Cancer J Clin, 2014,64( 1 ) : 9-29.
5Varughese S, Jahangir KS, Simpson CE, et al. A paradigm shift in the treatment of advanced non-small cell lung cancer [J]. Am J Med Sci,2012,344(2) : 147-150.
6Sieglried JM, Gubish CT, Rothstein ME, et al. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer [J]. J Thorae Oncol, 2012,7(3) :485-495.
7Zheng XY. Guidelines of clinical research on Chinese new herbal medicines. Beijing:Medical Science and Technology Publishing House of China.2002 : 216-221.
8Therasse P,A rbuck SG. New guidelines to evaluate the response to treatment in solid tumors [J]. Nat Cancer Inst, 2000,92 (3) : 205-216.
9Saruwatari K,Yoh K. Maintenance therapy for advanced non-small cell lung cancer [J]. Gan To Kaga ku Ryoho, 2014,41 (8) :926-931.
10Hsia TC,Tu CY,Chen HJ. The impact of rescue or maintenance therapy with EUFR TKIs for Stage Ⅲ b-Ⅳ non-squamous non-small-cell lung cancer patients requiring mechanical ventilation [J]. BMC Anesthesiol, 2014, 14:55.
